High-risk human papillomavirus (HPV) infection is essential in the carcinogenesis of a substantial part of anogenital and oropharyngeal cancers and has additionally been shown to be a possible predictive marker for survival, especially in oropharyngeal cancer. Studies examining the influence of HPV status on survival after vulvar cancer have been conflicting and limited by small study populations. Therefore, the aim of this review and meta-analysis was to examine whether HPV status influences survival after vulvar cancer, which, to our knowledge, has not been done before. We conducted a systematic search of PubMed, Cochrane Library and Embase to identify studies examining survival after histologically verified and HPV tested vulvar cancer. A total of 18 studies were eligible for inclusion. Study-specific and pooled HRs of the 5-year OS and DFS were calculated using a fixed effects model. The I 2 statistic was used to describe heterogeneity. The studies included a total of 1,638
women with HPV tested vulvar cancers of which 541 and 1,097 were HPV-positive and HPV-negative, respectively. Fifteen studies included only squamous cell carcinomas. We found a pooled HR of 0.61 (95% CI: 0.48-0.77) and 0.75 (95% CI: 0.57-1.00) for 5-year OS and DFS, respectively. Across study heterogeneity was moderate to high (OS: I 2 5 51%; DFS: I 2 5 73%). In conclusion, women with HPV-positive vulvar cancers have a superior survival compared to women with HPV-negative, which could be of great clinical interest and provides insight into the differences in the natural history of HPV-positive and negative vulvar cancers.
Vulvar cancer is a rare malignancy that accounts for approximately 5% of all gynecological cancers. 1 It is mostly diagnosed in women over the age of 60, but in recent years, the incidence of vulvar cancer has increased in younger women. 2, 3 Based on histology, vulvar carcinomas can be divided into squamous cell carcinomas (SCC) and nonsquamous cell carcinomas, with SCC accounting for approximately 90% of all vulvar carcinomas. 4 The development of vulvar SCC follows two different pathways 5, 6 where one is associated with human papillomavirus (HPV) and the other is non-HPV associated. The non-HPV associated vulvar neoplasia typically occurs in older women and develops from chronic inflammatory skin disorders such as lichen sclerosus. [7] [8] [9] [10] The HPV-associated vulvar cancers represent approximately 40% of all vulvar SCCs. They often occur in younger women and are mostly of basaloid or warty morphology. HPV16 accounts for the majority of cases. 11 Beside vulvar cancer, persistent infection with HPV is also associated with other anogenital cancers and oropharyngeal cancer. 12 The HPV prevalence is varying at the different cancer sites, but HPV status has been shown to be a possible marker of prognostic relevance, especially in oropharyngeal cancer. Specifically, HPV-positive oropharyngeal SCCs have been shown to have a more favorable clinical outcome compared to HPV-negative, [13] [14] [15] [16] [17] which has led to more clinicians conducting HPV testing of oropharyngeal cancers to provide insight into the prognosis of the patient. [18] [19] [20] Previous studies have also compared the prognosis among women with HPVpositive and HPV-negative vulvar cancers; however, due to small study populations the studies are often inconclusive. Additional knowledge on possible differences in the prognosis of HPV-positive and HPV-negative vulvar cancers is of clinical interest and would add to our current knowledge on the natural history of vulvar neoplasia.
The aim of this study was to examine the influence of HPV status on survival in women diagnosed with vulvar cancer. In this systematic review and meta-analysis, we performed a search in different databases to identify all relevant literature to calculate a pooled HR of the survival among women with HPV-positive vulvar cancer compared to those with HPV-negative cancers, which, to our knowledge, has not been done before.
Material and Methods

Search strategy and eligibility criteria
A systematic literature search of the databases PubMed, Embase and Cochrane was performed up to 22 April 2017. Combinations of search terms for HPV, vulvar cancer and survival was used. The search was performed using Medical Subject Headings and Emtree headings as well as text and keyword searches. The searches were limited to English language publications, but no other restrictions on the searches were applied. Additionally, we reviewed the reference lists to identify other relevant studies. Studies were eligible for inclusion if survival outcomes after histologically verified vulvar cancers in relation to HPV status was evaluated. Survival had to be reported for HPV-positive and HPV-negative vulvar cancers separately. Only peer-reviewed studies were included and if the publication was a case report or conference abstract, it was excluded. To avoid including overlapping study populations the data source of the studies were evaluated. If study populations were found to overlap, data from the study with most complete information was used. All titles, abstracts and full texts were reviewed independently by two authors (C.L.R. and F.L.S.). Any inconsistencies in the identification of relevant articles were discussed to reach consensus.
The present study was carried out in accordance with the "preferred reporting items for systematic reviews and metaanalyses" (PRISMA) guidelines. 21 
Quality assessment
The Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group of the Dutch Cochrane Center have proposed a critical review checklist, 22 which includes assessing the quality of each included study. This assessment was achieved by evaluating the following information in each study: clear definition of study design; clear definition of study population and country of origin; clear definition of assessment of reported outcomes; clear definition of method applied for HPV testing; and a sufficient period of follow-up. If studies did not meet these criteria, they were excluded.
Data extraction
Data from the included studies was extracted by two authors (C.L.R. and F.L.S.) with disagreements resolved by discussion until consensus. The following data was extracted from each study: first author, year of publication and sample collection, country, age of women with vulvar cancer (mean, median, range), follow-up time, sample size, number of HPV-positive and -negative vulvar cancers, treatment modality, histology of tumor, International Federation of Gynecology and Obstetrics (FIGO) stage, HPV testing method, and survival end points. We examined different survival outcomes including overall survival (OS), disease free survival (DFS), disease specific survival (DSS) and progression free survival (PFS). Studies reporting recurrence free survival were included under DFS because of very similar definitions. 23 
Statistical analysis
Hazard ratios (HRs) were estimated based on the data available in individual studies. For studies reporting survival during their entire follow-up period, we estimated the 5-year HRs using a previously reported method by Moodie et al. 24 This method enables us to perform a meta-analysis including studies, who do not report survival at the same length of follow-up time. The individual HRs were included in a fixed effects meta-analysis model, weighing each study using the reciprocals of the estimated variances as weights. As a sensitivity analysis, the meta-analysis was also conducted excluding studies where the individual HR was based on data read manually from survival plots only. The pooled HR was considered significant if the CI did not overlap 1. A HR <1 indicated a better survival for women with HPV-positive vulvar cancers compared to HPV-negative. Heterogeneity across studies was evaluated with the I 2 statistic, which is the percentage of variation between studies. An I 2 value above 50%
was considered notable heterogeneity. Significance of the heterogeneity was evaluated by Cochran's Q-test, with a p values <0.05 considered significant. 25, 26 All analyses were conducted using the statistical software R, 27 with the package "meta". 28 
Results
Search results
A total of 668 records were identified in PubMed, Embase and Cochrane Library (Fig. 1 ). After removing duplicates (n 5 198), 470 records were reviewed for potential relevance.
What's new?
Persistent infection with certain HPV strains is associated with oropharyngeal and anogenital cancers, including vulvar cancers (VC). Does HPV status influence VC prognosis? In this new meta-analysis, the authors found that women with HPV-positive VC have a more favorable overall survival and disease-free survival compared to women with HPV-negative VC. Additional research on the differences between HPV-positive and HPV-negative VC would be of clinical interest, and would improve our understanding of the natural history of vulvar neoplasia.
We excluded 333 records based on review of titles and 94 records were subsequently excluded based on review of abstracts. Among the remaining 43 records, 25 were excluded based on review of full text articles. Thus, a total of 18 studies were included in the review and meta-analysis. Table 1 presents study characteristics and reported survival outcomes. The studies included a total of 1,638 women with HPV tested vulvar cancers of which 541 and 1,097 were HPV-positive and HPV-negative, respectively. The number of HC2, hybrid capture 2; p16 IHC, p16 immunohistochemistry; OS, overall survival; DSS, disease specific survival; DFS, disease free survival; PFS, progression free survival; yr, years. 29, 34 used in situ hybridization (ISH) and one study 40 used hybrid capture 2 (HC2). Finally, one study used p16 immunohistochemistry (p16 IHC) as a surrogate marker for HPV infection. 44 
Study characteristics
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Overall survival
Among the 12 studies reporting OS, eleven studies reported information on 5-year OS according to HPV status of the vulvar cancers. A total of 985 women with vulvar cancer were included in the meta-analysis, of which 342 and 643 were HPV-positive and HPV-negative, respectively. The percentages of women with vulvar cancer alive at 5 years after diagnosis ranged from 50-86% for HPV-positive and 43-71% for HPV-negative in the individual studies. Figure 2 presents the study-specific and pooled HR of the 5-year OS of HPVpositive vulvar cancers compared to HPV-negative vulvar cancers. Eight out of 11 studies showed that HPV-positive women with vulvar cancer had a better overall survival than HPV-negative. Of these, five had statistically significant better HR for 5-year OS. Three studies found that women with HPV-negative vulvar cancer had better survival, however, none of these HRs were statistically significant. The HRs ranged from 0.18 to 1.35 with moderate across study heterogeneity (I 2 5 51% (p 5 0.02)). Overall, women with HPVpositive vulvar cancers had a significantly more favorable OS 5 years after diagnosis compared to women with HPVnegative vulvar cancers with a pooled HR of 0.61 (95% CI: 0.48-0.77; p < 0.001). Four of the included studies 36, 43, 44, 46 reported survival curves for OS and in these studies data on 5-year OS for HPV-positive and HPV-negative vulvar cancers were extracted manually from the survival curves. However, in a sensitivity analysis, excluding these studies, the pooled HR was virtually unchanged [HR 5 0.69 (95% CI: 0.50-0.94; p 5 0.02)]. One study 44 used p16 IHC as a surrogate marker for HPV infection. In a sensitivity analysis, excluding this study, the pooled HR came out virtually unchanged [HR 5 0.69 (95% CI: 0.53-0.89; p < 0.01)].
In a study by Lee et al. 42 HPV DNA was detected in 15 of 56 women with vulvar cancer, who were all treated with radiotherapy. They reported a HR of 0.4 (95% CI: 0.2-0.9) for OS during the follow-up period. The HR was adjusted for age and tumor stage. The study was not included in the pooled HR because data on 5-year OS was not available.
Disease free survival Figure 3 shows the calculated individual and pooled HRs for 5-year DFS. Seven studies were included in the meta-analysis of 5-year DFS, including a total of 620 women with vulvar cancer of which 180 were HPV-positive and 440 were HPVnegative. The HRs ranged from 0.21 to 1.61. The pooled HR was 0.75 (95% CI: 0.57-1.00; p 5 0.049). Heterogeneity observed among studies was high [I 2 5 73% (p < 0.01)]. In a sensitivity analysis excluding one study 36 that only reported 5-year DFS on survival curves, we found no substantial change in the pooled HR (HR 5 0.77; 95% CI: 0.57-1.04; p 5 0.083). The study by Lavorato-Rocha et al. 39 did not report information on 5-year DFS; however, they found no association between HPV status and DFS during the entire follow-period of the study, which was at least 5 years. Specifically, they reported an unadjusted relative risk (RR) for DFS of 1.00 (p 5 0.3) for HPV-positive vulvar cancers compared to HPV-negative vulvar cancers.
Other survival outcomes
Four studies examined only DSS. 30, 34, 35, 41 A larger study by Knopp et al. 34 included 217 women with vulvar SCC. They found that women with HPV-positive vulvar SCC had a RR of 0.4 (95% CI: 0.2-0.9) of dying from vulvar cancer within 5 years compared to women with HPV-negative vulvar SCC. Smaller studies by Ansink et al. 30 and Hay et al. 41 also indicated that women with HPV-positive vulvar cancer have a superior DSS compared to HPV-negative. In contrast, van de Nieuwenhof et al. 35 examined 130 vulvar SCC including a total of 45 HPV-positive tumors, of which 35 were positive for a high-risk HPV type. They reported that based on highrisk HPV positivity, no significant difference could be shown on the disease-specific survival curve (p 5 0.646) compared to HPV-negative vulvar cancers.
Four studies 42, [44] [45] [46] reported data on PFS in women with vulvar cancer according to HPV status. Generally, the studies reporting PFS consisted of smaller study populations. 42, 45, 46 Three studies reported an unadjusted overall HR of respectively 0.24 (95% CI: 0.10-0.56), 0.37 (95% CI: 0.18-0.70), and 0.68 (95% CI: 0.26-1.75). [44] [45] [46] When the studies additionally adjusted for age and stage, the HRs for PFS were virtually unchanged and the 95% CIs were overlapping with the unadjusted HR. Lee et al. 42 reported an age and stage adjusted HR of 0.20 (95% CI: 0.1-0.6) for PFS. All the studies reporting PFS also reported either 5-year OS or DFS and were therefore included in the pooled meta-analysis of these survival outcomes. In three of the studies reporting HR for 5-year OS the results were not statistically significant.
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Discussion
To our knowledge, this is the first systematic review and meta-analysis evaluating the impact of HPV status on survival outcomes after vulvar cancer. We found that women with HPV-positive vulvar cancers had a significantly superior OS as well as DFS compared to HPV-negative. Additionally, studies examining other survival outcomes, including DSS and PFS, also pointed towards a more favorable survival among women with HPV-positive vulvar cancers compared to HPV-negative.
Various mechanisms might explain these findings. HPV status of the tumor could determine the molecular profile of the cancer, which consequently influence the subsequent response to therapy. HPV-positive vulvar cancers might have a higher sensitivity to radiotherapy, which has also been suggested for head-and-neck cancers. 18, 47 Different biological factors are thought to explain the improved response to radiotherapy in HPV-positive head-and-neck tumors. These include impaired DNA repair, decreased repopulation signaling pathways, downregulation of cell cycle control mechanisms, rapid resolution of cell hypoxia, and an enhanced immune response. 47 Specifically, it has been suggested that the TP53-mediated apoptosis following radiation is increased in HPV-positive head and neck SCC. 48 In HPV-infected cells, the E6 and E7 HPV genes also downregulate the retinoblastoma protein (pRb), which normally functions to prevent excessive cell growth by inhibiting cell cycle until a cell is ready to divide. 49 Without this regulation, the cell cycle will continue unchecked, which leads to the accumulation of radio-induced DNA damage and this eventually leads to cell death because of mitotic catastrophe. 50 However, results from studies evaluating the radiosensitivity of HPV-positive vulvar SCCs compared to HPV-negative are conflicting 37, 42 and thus, we have not yet a full understanding of the molecular basis of a possibly higher radiosensitivity in HPV-positive vulvar cancers. Additionally, some studies have shown that HPV-negative vulvar intraepithelial neoplasia (VIN) has a more aggressive clinical presentation with higher progression rate compared to HPV-positive VIN. 4, 45, 51, 52 These findings could indicate that HPV-positive vulvar neoplasia in general develops through a less aggressive pathway and has a more favorable prognosis in all stages of carcinogenesis.
There was substantial variation in the HRs of 5-year OS and DFS across studies, with HRs ranging from 0.18 to 1.35 for OS and 0.21 to 1.61 for DFS. Generally, the studies found a favorable survival for HPV-positive vulvar cancers compared to HPV-negative, but three study-specific HRs were above 1, 33, 37, 46 however, all had very wide confidence intervals, and in two studies the HPV prevalence was relatively low. 33, 37 In addition, even though our extrapolated HR, based on data read from Kaplan-Meier curves, for 5-year OS was 1.11 (95% CI: 0.39-3.19) in the study by Weberpals et al. they reported an OS of 0.74 (95% CI: 0.30-1.86) for HPVpositive vulvar cancers compared to HPV-negative for the entire study period. 46 This relative risk is similar to our pooled HR for OS. The potential source of variation across studies could possibly be explained by difference in geographical region, publication year, age of women with vulvar cancer, treatment modalities and stage of the vulvar cancers, design of the studies, and HPV detection methods. This is the first review and meta-analysis to examine differences in survival outcomes in HPV-positive and HPVnegative vulvar cancers. The strengths of this review and meta-analysis include the comprehensive search of literature and two authors independently reviewing the titles, abstracts and full text articles and conducting the data extraction. Previous studies have been limited by small study populations, but in this meta-analysis, we combined the power of numerous studies comprising a total of 1,638 women with HPV tested vulvar cancer, which provided more precise estimates of effects. Among the 18 included studies, only three included other histological types than vulvar SCC, with the proportion of SCC amounting to 86%, 29 96% 31 and 98%, 40 respectively. However, our study also has some limitations. In four studies, data was read manually from Kaplan-Meier curves, which made these HRs less reliable, however, in sensitivity analyses where we excluded these studies, the pooled HRs were virtually unchanged. Establishing HPV status of vulvar cancers could be an important factor when planning the most optimal clinical management and follow-up strategy after treatment. Younger women often develop HPV-positive vulvar cancer, which seems to have a less aggressive nature and favorable prognosis. This might suggest that HPV-positive vulvar cancers could be treated more conservatively taking into account the potentially higher sensitivity to radiation therapy. Furthermore, the higher progression rate of HPV-negative tumors indicates that these women would benefit from an intensive follow-up strategy to detect progression or recurrence of the cancer. However, more studies are needed to guide the most optimal management and follow-up strategy taking into account important prognostic factors, such as HPV status of the vulvar cancers, age of the women with vulvar cancer, tumor stage and lymph node metastasis. Also, it might be useful to perform an individual participant data (IPD) metaanalysis, in which the original research data are sought directly from the researchers responsible for each study.
In conclusion, this systematic review and meta-analysis suggests that HPV-positive vulvar cancers have a more favorable prognosis compared to HPV-negative. These results add to the knowledge of the natural history of vulvar cancers and point to a possible clinical value of HPV testing of vulvar cancers when planning the most optimal management and follow-up strategy. Still, an IPD meta-analysis or larger studies that are able to take into account other prognostic factors are needed to provide additional evidence.
